Expression of hnRNPK & Claudin-4 in HCV-Induced Early HCC and Adjacent Liver Tissue by Hammam, Olfat et al.
  
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2017 Aug 15; 5(5):595-602.                                                                                                                                                         595 
 
ID Design 2012/DOOEL Skopje, Republic of Macedonia  
Open Access Macedonian Journal of Medical Sciences . 2017 Aug 15; 5(5):595- 602. 
https ://doi.org/10.3889/oamj ms.2017.092 
eISSN: 1857- 9655 
Basic Science 
 
 
  
 
Expression of hnRNPK & Claudin-4 in HCV-Induced Early HCC 
and Adjacent Liver Tissue 
 
 
 
Olfat Hammam
1*
, Mona Magdy
1
, Amgad Anas
2
, Ali Abdel Rahim
2
,
 
Mohamed Heedaya
3
, Ahmed Helmy
3 
 
1
Department of Pathology
 
Theodor Bilharz Research Institute (TBRI), Imbaba, Giza, Egypt; 
2
Department of Hepato-
gastroenterology,Theodor Bilharz Research Institute (TBRI), Imbaba, Giza, Egypt; 
3
Department of General Surgery, Theodor 
Bilharz Research Institute (TBRI), Imbaba, Giza, Egypt 
 
Citation: Hammam O, Magdy M, Anas A, Rahim AA, 
Hedaya M, Helmy A. Expression of hnRNPK & Claudin-4 
in HCV Induced Early HCC and Adjacent Liver Tissue. 
Open Access Maced J Med Sci. 2017 Aug 15; 5(5):595-
602. https://doi.org/10.3889/oamjms.2017.092 
Keywords:  hnRNPK; Claudin-4; eHCC; Metavir; EMT; 
cirrhosis. 
*Correspondence:  Professor Dr Olfat Hammam. 
Pathology Department, Theodor Bilharz Research 
Institute, El-Nile Street,Warrak El-Hadar, Imbaba P.O. 
Box 30, Giza 12411, Egypt. Mobile number: 
20201001815577. E-mail: totoali1@hotmail.com 
Received: 14-May-2017; Revised: 16-Jun-2017; 
Accepted: 17-Jun-2017; Online first: 31-Jul-2017 
Copyright:  © 2017 Olfat Hammam, Mona Magdy, Amgad 
Anas, Ali Abdel Rahim, Mohamed Heedaya, Ahmed 
Helmy. This is an open-access article distributed under 
the terms of the Creative Commons Attribution-
NonCommercial 4.0 International License (CC BY-NC 
4.0). 
Funding:  This research did not receive any financial 
support. 
Competing Interests:  The authors have declared that no 
competing interests exist. 
Abbrev iations: eHCC = Early Hepatocellular  Carcinoma; 
hnRNPs = RNA-binding proteins; EMT= Epithelial 
Mesenchymal Transition; HNRNPK = Heterogeneous 
nuclear ribonucleoprotein K; HCV = Hepatitis C Virus; 
HCV = Hepatitis B Virus; VEGF = Vascular Endothelial 
Growth Factor;  TJs = Tight Junctions;  TBRI = Theodeor 
Bilharz Research Institute; HPFs = High Power Fields; % 
= Percentage; HGeHCC = High Grade Early 
Hepatocellular  Carcinoma; LGeHCC = Low Grade Early 
Hepatocellular  Carcinoma. 
 
 
 
 
Abstract  
BACKGROUND: HCC in Egy pt usually  occurs in HCV cirrhotic liv ers with poor  prognosis due to late diagnosis. 
High hnRNPK & low Claudin-4 prof iles indicate Epithelial Mesenchy mal Transition (EMT), malignant  
transf ormation and high-grade tumours.  
AI M: We studied the immunohistochemical expression of  hnRNPK and Claudin -4 in HCV induced early  HCC 
(eHCC) and adjacent liv er tissue in Egy ptian patients to improv e eHCC detection in cirrhotic liv ers with better 
curativ e therapy  options. 
METHOD: We studied the immunohistochemical expression of  hnRNPK and Claudin-4 in  100 Egy ptian patients 
resection specimens of  HCV induced early  HCC (eHCC) and adjacent liv er tissue, in order to improv e eHCC 
detection in cirrhotic liv ers, thus improv ing their therapeutic options.   
RESULTS: Early  HCC grade signif icantly  directly  correlated with nuclear hnRNPK/5HPFs count and inv ersely 
correlated with Claudin-4 expression %, with a conv erse correlation between hnRNPK and Claudin-4. Moreov er in 
eHCC, combined hnRNPK  30/5HPFs & Claudin-4 40% signif icantly  distinguished low grade eHCC (G1) f rom 
high grade eHCC (G2&G3), with sensitiv ity 97% & specif icity  69.7% f or hnRNPK 30/5HPFs, and with sensitiv ity 
70% & specif icity 94.3% f or Claudin-4  40%. Moreov er in the adjacent liv er, both markers expressions 
signif icantly directly correlated with each other and with METAVIR f ibrosis score but not with activity. Furthermore, 
58% of  eHCCs showed hnRNPK 30 Claudin-4 < 40% prof ile, indicating EMT ty pe 3, compared to 26% with  
hnRNPK 30 Claudin -4 10% prof ile in adjacent cirrhotic/ precirrhotic liv er, with signif icant use of  combined 
hnRNPK  30/5HPFs & Claudin 4  10% as eHCC prediction cut offs in cirrhosis (p < 0.05).  
CONCLUSION: Combination of  hnRNPK and Claudin-4 can indicate early  HCC dev elopment in HCV cirrhotic 
liv ers using hnRNPK  30/5HPFs & Claudin-4  10% cut off s. Also, combination of  hnRNPK  30/5HPFs & 
Claudin-4  40% can distinguish low grade eHCC (G1) f rom high grade eHCC (G2&G3).  
 
 
 
 
Introduction 
 
In Egypt, HCC is one of the commonest 
cancers [1-2]. It occurs with cirrhosis [3] since it leads 
to alteration of hepatocyte proli feration and promotion 
of tumorigenesis [4-6]. Early HCC treatment is 
curative [3]. Nevertheless, usually, HCCs have a poor 
prognosis due to late diagnosis and lack of effective 
therapy options [6]. Accordingly, early detection of 
HCC in cirrhotic patients is mandatory [3].  
 Heterogeneous nuclear RNA-binding proteins 
(hnRNPs) are crucial for RNAs control, mRNA export, 
turnover, localization, and translation [7-8]. Their 
aberrant expression is associated with cancer cell 
proli feration, angiogenesis, invasion, epithelial 
mesenchymal transition (EMT) and metastasis [8]. 
Heterogeneous nuclear ribonucleoprotein K 
(hnRNPK) is a potential tissue biomarker for early 
detection of HCC [8-9]. It is a DNA & RNA binding 
protein [10] and contributes to chromatin remodeling, 
transcription and translation [11]. It is distinguishable 
from the other hnRNPs by its capability to interact with 
numerous proteins through its K interactive region [12-
13] that fits it in the center of a network to influence 
diverse cellular processes. HNRNPK is a potential 
tumor suppressor [10]. Its knockout results in reduced 
survival and increased tumorigenicity [12-13]. Its 
overexpression is associated with poor clinical status 
[10].  
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In hepatitis, hnRNPK is important for HCV 
pathogenesis [3, 8, 9]. It shows similar sequences 
with HCV core protein binding domain [3]. Moreover, 
hnRNPK is involved in the multistep process of 
hepatocarcinogenesis of both HBV replication and 
HCV pathogenesis with eventual cirrhosis and HCC 
[3], [8]. In this context, an increase of HCC in Egypt is 
due to high HCV prevalence particularly in cirrhotic 
patients compared to the declining incidence of HBV, 
since Egypt exhibits the highest HCV prevalence 
worldwide [14-16]. 
In HCC, hnRNPK overexpression is a marker 
for HCC [3, 11]. Positive tissue hnRNPK staining is an 
indicator of HCC and facilitates accurate early HCC 
distinction from high-grade dysplasia and other small 
nodules, which can be extremely challenging [3]. 
Moreover, hnRNPK expression in the early and late 
HCC is reported to be > 3 folds higher and stronger 
than adjacent cirrhotic [3] or normal liver [16], due to  
the nuclear shift of K protein from the cytoplasm into 
the nucleus in tumours.  
In addition, hnRNPK overexpression 
significantly correlates with the increased tumour size, 
active tumour growth, intrahepatic micrometastasis 
and microsatellite nodules formation [3].  
In the same context, increased nuclear levels 
of K protein in cancers plays a role in the altered 
telomeric processes [17], exerts antiapoptotic effect 
on cancer cells independently of p53 status [11], 
activates c-myc promoter in hepatocytes in response 
to mitogens and following liver injury [17], and 
activates VEGF transcription by selective binding to 
VEGF promoter [8]. Since Epithelial Mesenchymal 
Transition (EMT)-angiogenesis-stem cell -like crosstalk 
is a key factor for HCC [18], the t ransformed tumour 
cells acquire stem cell features, show multidrug 
resistance, and induce local recurrence [18-19], 
metastasis & cancer progression [20]. Also, hnRNPK 
silencing significantly decreases EMT phenotype in 
cancer cells [8, 21].  
In this regard, loss of critical junction proteins 
-including Claudins - leads to loss of epithelial cell 
adhesion, thus represents the first step of EMT [22]. 
Claudins are trans membrane proteins and important 
components of tight junctions (TJs) [23-24] that act as 
cell adhesion molecules, thus preserving cohesion in 
the tumour mass, suppressing cell proli feration & 
tumorigenesis, and function as cell migration barrier 
[24]. Moreover, Claudine expression patterns affect 
the tumour behavior [23]. Downregulation of several 
Claudins in cancer is consistent with the disruption of 
TJs during tumourigenesis [23] since low expression 
or loss of TJs is associated with malignant 
transformation and characterizes the highly metastatic 
cancers [23].  
Claudin-4 is one of the most frequently 
dysregulated Claudins [24-26]. Its low expression 
indicates poor prognosis in oesophagal and colorectal 
cancers [24]. Nevertheless, it is upregulated in other 
malignancies, including breast, esophageal, gastric, 
pancreatic, prostate and uterine cancers [24].  
In the liver, impaired Claudin-4 expression in 
biliary tract cancers is associated with less 
differentiated and more invasive phenotypes [27]. 
Hence it became a candidate for Claudin based 
targeted therapies [27-29]. More importantly, Claudin-
4 protein is undetectable in HCC and normal 
hepatocytes compared to normal expression by 
normal cholangiocytes [27-28]. Nevertheless, it is 
expressed by severely damaged hepatocytes [30]. 
Hence, Claudin-4 distinguishes biliary from 
hepatocytic tumours [27, 30-31].  
Since markers combination improves 
diagnosis [3], we studied the immunohistochemical 
expression of hnRNPK and Claudin-4 in HCV induced 
early HCC (eHCC) and adjacent liver tissue in 
Egyptian patients to improve eHCC detection in 
cirrhotic livers with better curative therapy options.  
 
 
Material and Methods 
 
The study was held on 100 HCC resection 
specimens with a history of HCV infection, obtained 
retrospectively from archival paraffin blocks at 
pathology department Theodeor Bilharz Research 
Institute (TBRI) (2010-2015).  
A- Inflammatory activity and fibrosis in the adjacent  
liver tissue were evaluated using METAVIR 
scoring system [32] as follows:  
 A for inflammatory activity: A0: No activity. A1: 
Mild. A2: Moderate. A3: Marked.  
 F for portal fibrosis: F0:  No portal fibrosis. F1: 
Portal fibrosis without septa. F2: Portal fibrosis 
with rare septa. F3: Numerous septa without 
cirrhosis. F4: Cirrhosis.  
B- HCC graded as follows [33]:  
 Well differentiated (G1): Thin plates with 1-3 
hepatocytes thick, minimal nuclear atypia, 
doubled nuclear density and common pseudo 
glands.  
 Moderately differentiated (G2): Trabeculae > 4 
cells thick, large cells with nucleoli, pseudo glands 
and bile.  
 Poorly differentiated (G3): Large cells in solid 
sheets with hyperchromatic nuclei, marked 
pleomorphism and rare trabeculae or bile.  
 We considered G1 as low grade (Fig. 1), while G2 
& G3 as high grade [34].  
 Hammam et al. Expression of hnRNPK & Claudin-4 in HCV Induced Early HCC and Adjacent Liver 
_______________________________________________________________________________________________ _______________________________  
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2017 Aug 15; 5(5):595-602.                                                                                                                                                         597 
 
C- Immunohistochemical technique: 
Immunohistochemistry for hnRNPK & 
Claudin-4 was performed on tumours and adjacent 
non tumorous tissue sections cut from the paraffin 
blocks and stained with anti-human hnRNPK & 
Claudin-4 monoclonal primary antibodies (Santa Cruz 
Biotechnology, CA, USA) at 1:150 dilution. Slides 
were sectioned at 4μm onto positively charged slides 
(Superfrost plus, Menzel-Glaser, Germany) and the 
slides were stained on an automated platform the 
(Dako Autostainer Link 48). Heat induced antigen 
retrieval was used for 30 min at 97°C in the high-PH 
EnVision™ FLEX Target Retrieval Solution, and the 
primary antibody was used at a dilution of 1 in 100. 
The detailed histopathological assessment was done 
regarding confirmation of diagnosis and grading of 
malignant cases.  
 
Figure 1: H&E Low (G1) & High (G2 & G3) early HCC (eHCC) and 
the adjacent liver. (A) High (G2-3) early HCC (eHCC) shows 
moderate nuclear anaplasia and pseudoglandular forms. The 
adjacent liver shows steatosis (H&E ×100). (B) High grade (G2-3) 
early HCC (eHCC), shows moderate to high nuclear anaplasia, 
pseudoglandular forms and bile (H&E × 200). (C) Low grade (G1) 
early HCC (eHCC) shows low grade nuclei and compact 
architecture, among a background cirrhotic liver (H&E × 100) 
 
D- Evaluation of the immunostaining: 
 HNRNPK: Only nuclear staining was counted per 
5 High Power Fields (5HPFs). Positivity cut off at 
10% was established.  
 Claudin-4: Semiquantitative H score for staining 
intensity and % of expression was used. Positivity 
cut off at >10% was established [35].  
 
Statistical analysis 
SPSS software version 18 was used for data 
management and analysis. Quantitative data were 
presented as mean ± SD. Qualitative data were 
presented as frequencies and percentages. 
Spearman’s correlation coefficient was calculated to 
assess the relationship between variables. Tests were 
considered statistically significant when P< 0.05. Cut 
off values for both markers were chosen with 
sensitivity and specificity evaluation.  
 
Results 
 
I - Mean hnRNPK & Claudin-4 expression in HCC 
compared to the adjacent non tumorous liver:  
A- Claudin-4:  
All of our cases (whether HCCs or their 
adjacent liver) showed low Claudin-4 expression 
profile regarding the staining intensity -weak & 
negative cytoplasmic staining- compared to the 
moderate and strong expression in bile ducts as 
internal control. Non exhibited high Claudin-4 
expression profiles (Fig. 2).  
Table 1: Mean expression values of hnRNPK & Claudin-4  in 
eHCC &  adjacent liver tissue 
 T- test  Anova 
test  
N Mean 
expression 
Std. D eviation Std. Error 
Mean 
Claudin-4 
expression %   
eHCC vs. adj acent li ver  
Adjacent li ver 
liver  
100 .0000 .00000 .00000 0.000**  
eHCC 100 31.2400 15.20043 1.52004 
eHCC grade 
G1 
25 
25% 
46.8400 9.15915 1.83183 
0.000**  
G2 
54 
54% 
30.7963 6.19915 0.84360 
G3 
21 
21% 
25.2381 24.11204 5.26168 
METAVIR acti vity i n adjacent li ver  
A1 
8 
8% 
0.000 0.000 0.000 
0.637 
A2 
8 
8% 
0.000 0.000 0.000 
A3 
84 
84% 
1.0714 4.46347 0.48700 
METAVIR fibrosis i n adjacent li ver  
F3 
94 
94% 
0.000 0.000 0.000 
0.000**  
F4 
6 
6% 
15.000 8.94427 3.65148 
hnRNPK 
nuclear 
count/5HPFs  
eHCC vs adjacent liver 
Adjacent li ver  100 23.8600 7.58656 .75866 0.000**  
eHCC 100 40.1400 17.05133 1.70513 
eHCC grade 
G1 25 24.9600 3.86738 0.77348 0.001*  
G2 54 36.6667 8.81465 1.19952 
G3 21 67.1429 11.36348 2.47971 
METAVIR acti vity 
A1 8 29.2500 2.54951 0.90139 0.060 
A2 8 20.5000 9.03960 3.19598 
A3 84 23.6786 7.56364 0.82526 
METAVIR fibrosis  
F3 94 23.2234 7.35016 0.75811 0.001*  
F4 6 34.0000 1.54919 0.63246 
**Significance differences between groups  by Anova Test ( p=0.001). *Significance 
differences between groups  by Anova Tes t (p<0.05).  
 
In adjacent liver, only 6 cases (6%) exhibited 
weak Claudin-4 in >10%. In contrast, the majority of 
cases (94%) significantly showed 0% - < 10% 
Claudin-4, with mean expression value 0% compared 
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to 31.24% + 15.20 in HCC (P < 0.001) (Tables 1 & 2).  
 
B- hnRNPK: 
Cytoplasmic and nuclear hnRNPK expression 
in eHCC & adjacent liver was noticed. Only the 
nuclear expression was counted (Fig. 2).  
 
Figure 2: Immunohistochemistry expression hnRNPK & Claudin-4 in 
eHCC and adjacent liver. (A) Cirrhotic liver nodules are showing 
nuclear hnRNPK (in focus), (IHC, DAB, ×100). (B) High grade (G2-
3) early HCC (eHCC), showing nuclear (in focus) and cytoplasmic 
hnRNPK expression, (IHC, DAB, ×200).(C) Low grade (G1) early 
HCC (eHCC) and cirrhotic liver nodules with foci of weak 
cytoplasmic Claudin-4 (in focus), compared to normal moderate 
Claudin-4 in proliferated bile ductules (as an internal control) (IHC, 
DAB, ×200). (D) High grade (G2) early HCC (eHCC) shows weak 
cytoplasmic Claudin-4 (in focus), (IHC, DAB, ×100) 
Our study showed that all of the non tumorous 
liver tissue adjacent to HCC significantly exhibited 
increased nuclear hnRNPK from a mean nuclear 
expression value 23.86 ± 7.587/5HPFs to 40.14 ± 
17.05/5HPFs in HCC (P < 0.001) (Tables 1 & 2; Fig. 
3a).  
 
II - Regarding eHCC grade:  
Overall, nuclear hnRNPK expression 
significantly directly correlated with HCC grade and 
inversely correlated with Claudin-4 expression % (P  = 
0.000) (Table 3; Figs. 3a-3b) in contrast to Claudin-4 
expression %.  
Low grade eHCC (G1) significantly showed > 
40% weak cytoplasmic Claudin-4 expression in 70% 
of cases, with mean expression value of 46.84% + 
9.16, compared to 30.80% + 6.20 in high grade (G2) 
eHCC, and to 25.24% + 24.11 in high grade (G3) 
HCC.  
Table 2: hnRNPK & Claudin-4 expression among the studied 
cases in early HCC & adjacent pre-cirrhotic/cirrhotic liver 
regarding the chosen cut offs 
I- HCC 
 
hnRNPK   
nuclear  
count  > 
30/5HPFs 
cut off  
hnRNPK   nuclear  
count < 30/5HPFs 
cut off  
Claudin-4 % 
of expression 
> 40% cut off  
 
Claudin-4 % of 
expression 
< 40% cut off  
 
Low grade eHCC 
(G1) 
3 % 
N = 2 
69.7% 
N = 23 
70.0% 
N = 21 
5.7% 
N = 4 
High grade 
eHCC  (G2) 
65.7% 
N = 44 
30.3% 
N = 10 
6.7% 
N = 2 
74.3% 
N = 52 
High grade 
eHCC (G3)   
31.3% 
N = 21 
0% 
N = 0 
23.3% 
N = 7 
20% 
N = 14 
Significance   P = 0.000**  P = 0.000**  
II-Adjacent li ver  
 
 
 
  
hnRNPK   
nuclear  
count  >30 
/5HPFs 
cut off  
hnRNPK   nuclear 
count < 30/5HPFs cut 
off  
 
Claudin-4 % of 
expression 
< 10% cut off  
 
Claudin-4 % of 
expression 
> 10% cut off  
 
 
Inflammation ac ti vity 
METAVIR acti vity  
1 
 
17.2% 
N = 5 
 
4.2% 
N = 3 
12.8% 
N = 12 
0% 
N = 0 
METAVIR acti vity  
2 
 
3.4% 
N = 1 
 
9.9% 
N = 7 
8.5% 
N = 8 
0% 
N = 0 
METAVIR acti vity  
3 
79.3% 
N = 23 
85.9% 
N = 61 
78.7% 
N = 74 
100% 
N = 6 
Significance 
 
P = 0.063 
 
P = 0.549 
Fibrosis 
METAVIR 
fibrosis 3 
79.3% 
N = 23 
100% 
N = 71 
96.8% 
N = 91 
50% 
N = 3 
METAVIR 
fibrosis 4 
20.7% 
N = 6 
0% 
N = 0 
3.2% 
N = 3 
50% 
N = 3 
Significance                    P = 0.000**                       P = 0.002*  
**p, Significant differences between groups  by C hi Squar e Test (p<0.01); *p,  Significant 
differences between groups  by Chi Square Test (p  < 0.05).  
 
 
In contrast, 94.3% of high grade eHCC (G2 & 
G3) showed 0% - < 40% of cytoplasmic Claudin-4 
compared to only 5.7% of G1 (P = 0.000) (Tables 1-2; 
Figs. 2-3b).  
 
Figure 3: Statistical analysis charts for evaluation of hnRNPK & 
Claudin-4 expression in early HCC (eHCC) & adjacent liver. (A) 
Values of mean nuclear hnRNPK count /5HPFs & mean Claudin-
4% of expression in early HCC (eHCC) & adjacent liver. (B) Cut offs 
of hnRNPK/5HPFs & Claudin-4 expression%   among the studied 
cases regarding early HCC (eHCC) grade. (C) hnRNPK & Claudin-4 
expression profiles in early HCC (eHCC)  regarding Epithelial 
Mesenchymal Transition (EMT). (D) hnRNPK & Claudin-4 
expression profiles in cirrhotic/precirrhotic adjacent liver regarding 
Epithelial Mesenchymal Transition (EMT) 
 
Accordingly, we chose Claudin-4 > 40% as a 
cut off to distinguish low grade eHCC (G1) from high 
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grade eHCC (G2&G3) (P  = 0.000) (Tables 1-2), with 
sensitivity 70%, specificity 94.3%, false positive rate 
5.7%, and false negative rate 30%.  
On the other hand, approximately 70% of low 
grade eHCC (G1) significantly showed nuclear 
hnRNPK < 30/5HPFs, with mean nuclear expression 
value 24.96 + 3.87/5HPFs compared to 36.67+ 
8.81/5HPFs for high grade (G2) eHCC, and to 67.14 + 
11.36/5HPFs for high grade (G3) HCC (P = 0.000). In 
contrast, 97% of high grade HCC (G2 & G3) 
significantly exhibited nuclear hnRNPK > 30/5HPFs 
(Tables 1-2; Fig. 3b).  
Accordingly, we chose nuclear count of 
hnRNPK > 30/5HPFs as a cut off to distinguish low 
grade eHCC (G1) versus high grade eHCC (G2&G3) 
(P = 0.000) (Tables 1-2), with sensitivity 97%, 
specificity 69.7%, false positive rate 30.3%, and false 
negative rate 3%.  
 
III - Regarding METAVIR fibrosis & activity scores 
in adjacent non-tumorous liver tissue:  
Most of our cases showed pre-cirrhotic (F3) 
rather than complete cirrhotic nodules (F4) due to the 
clinical difficulty of obtaining liver biopsies in cirrhotic 
patients. Overall, both markers expressions 
significantly directly correlated with each other and 
with fibrosis score (P = 0.000) (Table 3; Fig.3a). Since 
94% of cases showed Claudin-4 < 10%, using 
Claudin-4 > 40% as a cut off for adjacent non HCC 
liver evaluation was statistically invalid compared to 
hnRNPK > 30/5HPFs & Claudin-4 < 10% as 
statistically valid cut offs in this regard.  
Our study showed significant direct correlation 
between Claudin-4 < 10% and degree of liver fibrosis. 
About 96.8% of F3 and 3.2% of F4 (total number = 94 
cases) significantly showed Claudin-4 < 10% (P = 
0.000). Only 6% (3 F3 & 3 F4 cases) expressed weak 
cytoplasmic Claudin-4 > 10% in 15% + 8.94 of 
hepatocytes, mostly at the periphery of the 
precirrhotic/cirrhotic nodules, with inconspicuous 
staining in nodules' centers (P < 0.000) (Tables 1-3; 
Figs 2-3a).  
On the other hand, 29% of 
cirrhotic/precirrhotic nodules (23 F3 & 6 F4 cases) 
significantly exhibited nuclear hnRNPK in  > 30/5HPFs 
of hepatocytes (P<0.001) (Tables 1-2; Fig. 3a). Also 
the study showed significant  increase of the mean 
hnRNPK nuclear expression from 23.22 + 7.35/5HPFs 
in F3 up to 34 + 1.55/5HPFs in F4 (P = 0.001) (Table 
1; Fig. 3a).  
Nevertheless, neither hnRNPK nor Claudin-4 
showed a significant difference or correlation with 
inflammatory activity scores (Tables 1- 3). 
Furthermore, both markers neither correlated with age 
or gender (Table 3).  
Table 3: Non-parametric correlation (Spearman's rho test) 
among the studied markers 
 Claudin-4% of 
expression  
hnRNPK   nuclear  
count/ 5HPFs 
eHCC  (N = 100)  
eHCC grade  
-0.519-**  
0.000 
0.829**  
0.000 
hnRNPK   nuclear count/ 
5HPFs 
-0.376-**  
0.000 
1 
Claudin-4% of expr ession 1 
-0.376-**  
0.000 
Adjacent liver   (N = 100)  
METAVIR  Fibrosis  
0.908**  
0.000 
0.368**  
0.000 
METAVIR acti vity  
0.100 
0.324 
-0.105- 
0.298 
hnRNPK   nuclear  count/  
5HPFs 
0.349**  
0.000 
1 
Claudin-4% of expr ession  1 
0.349**  
0.000 
Age  
-0.032 
0.753 
0.003 
0.975 
Gender  
0.160 
0.122 
0.023 
0.821 
**p:    Correlation is significant at 0.01 level (2-tailed); *p:  Correlation is significant at 0.05 
level (2-tailed); -p:  Inverse non par ametric Spear man's rho test's correlati on coefficient.  
 
IV - Regarding EMT in eHCC & adjacent cirrhotic / 
precirrhotic liver:  
In eHCC, 58% showed hnRNPK > 30/5HPFs 
Claudin-4 < 40% profile, indicating EMT, compared to 
only 12% for hnRNPK< 30/5HPFs Claudin-4 < 40% 
profile (P = 0.000) (Fig. 3c).  
On the other hand in adjacent cirrhotic / 
precirrhotic liver, only 26% exhibited hnRNPK  
30/5HPFs Claudin-4 < 10% profile, in contrast to 86% 
for hnRNPK  30/5HPFs Claudin-4 <10% (Fig. 3d), 
however with P>0.05.  
 
 
Discussion  
 
Since HCC occurs in cirrhosis, early HCC 
detection is mandatory [3]. EMT physiologically or 
pathologically represents the conversion of an 
epithelial cell to a mesenchymal phenotype, and 
classified into three types: embryogenesis (type 1), 
wound healing/ fibrosis (type 2) and malignancy (type 
3), [18, 36]. In cancer, EMT indicates drug resistance, 
local recurrence [18-19], progression and metastasis 
[21]. Since that cirrhosis alters hepatocyte proli feration 
and promotes tumorigenesis [4-6], and since hnRNPK 
is significantly expressed in eHCC, maintained in late 
HCCs [3], and contributes to HCV pathogenesis [3, 8-
9], and since hnRNPK positive tissue staining is an 
indicator of HCC [3], we evaluated its expression in 
HCV induced HCCs and in their adjacent 
cirrhotic/precirrhotic livers.  
 In this study, both cytoplasmic and nuclear 
hnRNPK expressions in HCC as well as in the 
adjacent liver were noticed. Despite that cytoplasmic 
hnRNPK indicates its overexpression [10], nuclear 
hnRNPK was also reported to be higher in 
proli ferating compared to resting hepatocytes [3, 17], 
which was similar to our findings. Moreover, nuclear 
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hnRNPK level was reported to be higher in neoplasms 
than in adjacent normal parenchyma in contrast to the 
cytoplasmic hnRNPK that remains unchanged in both 
neoplastic and surrounding tissues [17]. Therefore we 
counted only nuclear hnRNPK in our study. 
Furthermore,  since several positivity cut  offs  were 
identified for early and late HCCs [3], and to avoid 
tissue variations, we used hnRNPK nuclear count > 
10/5HPFs as positivity cut off.  
 In addition, stronger nuclear hnRNPK was 
reported in HCC in comparison to fainter nuclear 
staining in cirrhosis [3]. This is due to hnRNPK 
translocation into the nucleus [3, 17], which reflects its 
involvement in altered DNA and/or RNA in malignancy 
[17]. Nevertheless, our study showed rather moderate 
to strong nuclear hnRNPK in adjacent  cirrhotic / 
precirrhotic liver, with a significant increase of the 
mean nuclear hnRNPK count in HCCs compared to 
adjacent cirrhotic liver,  confirming the critical role of 
hnRNPK in hepatocytes proliferation, differentiation 
and tumorigenesis promotion in cirrhotic liver [10].  
 Regarding Claudin-4, all of our cases -
whether HCC or adjacent liver- showed low Claudin-4 
expression profile (weak & negative cytoplasmic 
staining compared to the moderate and strong 
expression in bile ducts) since bile ducts used as an 
internal control as mentioned in Holczbauer et al., 
2013 [27] study. In the same context, absent Claudin-
4 expression in non tumorous hepatocytes & HCC 
was reported, in contrast to normal cholangiocytes 
and cholangiocarcinomas [27]. None of our cases 
exhibited high Claudin-4 expression profile. Coming 
along with Konstantinos et al., 2014 [35], this indicates 
molecular down regulation and subsequent high 
recurrence and low disease free survival rates, hence 
pointing to type 3 EMT [18, 36].  
Nevertheless, our study significantly showed 
increased Claudin-4 expression in HCC compared to 
the adjacent liver, in whic h weak cytoplasmic staining 
was detected. This came similar to Konstantinos et 
al., 2014 [35] where up regulation of Claudin-4 and 
other proteins in HCC was mentioned. In the same 
context, Holczbauer et al., 2013 [27] showed similar 
findings in some of their cases where Claudin-4 
expressed by the apical poles of the glandular and 
alveolar forms of HCC. Also, Konstantinos et al., 2014 
[35] reported -as other Claudins-, cytoplasmic staining 
pattern represented a loss of function & intracellular 
localization of Claudins, thus pointing to type 3 EMT 
[18, 36].  
 Moreover, Ojima et al., 2016 [34] classified 
eHCC into two pathologically distinct subtypes as high 
grade (HGeHCC) and low grade (LGeHCC). HGeHCC 
exhibited large tumor and nuclear sizes, high 
cellularity, structural atypia (including scirrhous 
pattern) with remarkable arterial and stromal invasions 
compared to LGeHCC. Similarly our study exhibited 
two distinct immunohistochemical profiles for the 
eHCC. High grade eHCC (G2&G3) significantly 
expressed hnRNPK > 30/5HPFs and Claudin-4 > 40% 
distinguishing it from low grade eHCC (G1), with 
sensitivity 97%, specificity 69.7%, false positive rate 
30.3%, false negative rate 3% for hnRNPK  > 
30/5HPFs cut off, and with sensitivity 70 %, specificity 
94.3%, false positive rate 5.7%, and false negative 
rate 30% for Claudin-4 > 40% cut off.  
 Furthermore, eHCC grade significantly 
directly correlated with nuclear hnRNPK/ 5HPFs count 
and inversely correlated with Claudin-4 expression %, 
with a converse correlation of hnRNPK with Claudin-4. 
In this regard, hnRNPK overexpression is considered 
as a marker for HCC [3, 11], besides that impaired 
Claudin-4 expression is associated with less 
differentiated and more invasive phenotype [27, 31], 
thus representing EMT type 3 [8, 18, 20, 36].  
 Despite that 50-60 years is the most frequent 
age range for HCC in Egypt [38], and despite 
association of increased Claudin-4 expression with 
female gender [37], our study showed no significant 
correlation between age, gender and both markers 
expression.  
Regarding the adjacent liver, the majority of 
our cases showed F3 fibrosis. In this context, it was 
reported that developing HCC without advanced 
fibrosis (F4) may be due to other factors in the 
pathogenesis of HCV [38]. In Egypt, despite the high 
incidence of HCC in cirrhosis, HBV infection (whether 
occult or combined HCV HBV infection forms), 
diabetes and smoking have synergistic effects in HCC 
development [14]. Nevertheless, most of our cases 
showed pre-cirrhotic (F3) rather than cirrhotic F4 due 
to the clinical difficulty of obtaining liver biopsies from 
cirrhotic patients.  
In our study, the mean expression of both 
markers significantly directly correlated with each 
other and with METAVIR fibrosis score but not 
inflammatory activity, with significant use of both of 
hnRNPK > 30/5HPFs & Claudin-4 < 10% cut offs (P < 
0.05).The majority expressed Claudin-4 < 10% 
particularly at the periphery of cirrhotic nodules. 
Similarly, according to Holczbaueret al., 2014 [27], it is 
due to bile duct proli feration [27], and according to 
Tsujiwaki et al., 2015 [28] is due to increased 
proli feration of progenitor cells that express Claudin-4, 
thus suggesting subsequent differentiation into mature 
hepatocytes.  
Nevertheless, majority of adjacent cirrhotic / 
precirrhotic liver (68%) expressed hnRNPK < 
30/5HPFs Claudin-4 < 10% profile in contrast to 26% 
for hnRNPK > 30/HPFs Claudin-4 < 10% profile 
suggesting type 2 EMT as healing and regenerative 
process [18]. This also indicates that not all EMT in 
cirrhosis undergo malignant transformation into HCC 
particularly that  the majority of those cases showed 
F3 pre-cirrhotic rather than F4 complete cirrhotic 
changes. Therefore it becomes compatible with 
incomplete rather than complete EMT with a chance 
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for reversal and healing [36] instead of malignant 
progression. This helps in identification of the leading 
factors of progression through finding of targeted 
therapeutic approaches to suppress nuclear hnRNPs 
translation [8, 11].  
In contrast, since increase expression of 
hnRNPK is associated with EMT [8], and since that 
loss of Claudins is the first step of EMT [22], 58% of 
our eHCCs significantly exhibited hnRNPK > 
30/5HPFs Claudin-4<40% profile compared to only 
12% for hnRNPK < 30/5HPFs Claudin-4 < 40% profile 
(P = 0.000), indicating EMT type 3 [18, 36] with drug 
resistance, local recurrence [18-19] & metastasis [21].  
In conclusion, high hnRNPK and low Claudin-
4 expressions indicate Epithelial Mesenchymal 
Transition (EMT), malignant t ransformation and high-
grade tumours. The combination of hnRNPK and 
Claudin-4 in HCV cirrhotic livers can indicate eHCC 
development through the significant use of hnRNPK > 
30/5HPFs & Claudin-4 < 10% as cut offs, hence 
helping in the identification of possible type 3 EMT 
that subsequently progresses to eHCC among those 
cirrhotic livers. Also, hnRNPK > 30/5HPFs Claudin-4 > 
40% profile can significantly distinguish low grade 
eHCC (G1) from high grade eHCC (G2&G3).  
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